Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) to a strong-buy rating in a research report report published on Thursday morning,Zacks.com reports.

Separately, Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $9.00 price objective for the company.

Eupraxia Pharmaceuticals Stock Up 7.9 %

Shares of EPRX opened at $3.13 on Thursday. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $5.58. The company has a market capitalization of $85.39 million and a P/E ratio of -4.35. The firm has a 50 day moving average of $2.67 and a 200 day moving average of $2.68.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.